Botulinum Neurotoxin Transport Protein Nerve Cell Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating neuromuscular disorders using botulinum neurotoxins face challenges such as short duration of efficacy, immune system stimulation due to foreign proteins, and the need for frequent injections, which can lead to antibody formation and reduced treatment intervals.
Innovation Solution
A transport protein (Trapo) with enhanced affinity to gangliosides, specifically modified to bind more effectively to nerve cells, is developed by modifying the heavy chain of botulinum neurotoxins, allowing for increased specificity and prolonged efficacy while minimizing immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If botulinum neurotoxins are used to treat neuromuscular disorders, then the release of neurotransmitters is inhibited, but the duration of efficacy is short and frequent injections are required
Solution Approach 1:
The patent modifies the heavy chain of botulinum neurotoxin by substituting specific amino acids (e.g., Tyr1117 to Ala, Phe1252 to Tyr, His1253 to Lys) to enhance binding affinity to ganglioside GT1b. This parameter change in the molecular structure increases the potency and extends the duration of action, allowing for less frequent injections while maintaining therapeutic efficacy.
2Reliability
If foreign proteins are used to treat neuromuscular disorders, then neurotransmitter release is inhibited, but the immune system is stimulated and antibody formation occurs
Solution Approach 1:
The patent applies local quality modification by specifically altering certain amino acid residues in the heavy chain while maintaining the overall protein structure and function. This localized modification enhances binding affinity to gangliosides, improving therapeutic reliability while potentially reducing immunogenicity by preserving key structural regions that the immune system recognizes as self-like.
3Power
If higher dosages of botulinum neurotoxins are used, then the therapeutic effect is stronger, but antibody formation increases and treatment intervals are reduced
Solution Approach 1:
The patent changes the molecular parameters of the neurotoxin by substituting amino acids to increase binding affinity to ganglioside GT1b by approximately 40-fold. This parameter change allows achieving stronger therapeutic effects at lower dosages, thereby reducing the risk of antibody formation and extending treatment intervals.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Trapo exhibits a significantly higher affinity to nerve cells, leading to increased efficacy in inhibiting neurotransmitter release, potentially extending treatment intervals and reducing antibody formation, thus providing a more potent and longer-lasting therapeutic effect with lower dosages.
Implementation Method 1
binds specifically to nerve cells and being received by these cells by endocytosis
Implementation Method 2
translocated from the acid, endosomal compartment into the cytosol of neurons
Data Source
AI summary
The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.